Patient characteristics
| Parameter . | MM patients (n = 102) . |
|---|---|
| Median age, years (range) | 64 (32-84) |
| Sex, male, n (%) | 57 (56%) |
| M-protein type | |
| IgG, n (%) | 51 (50%) |
| IgA, n (%) | 21 (21%) |
| IgM, n (%) | 0 (0%) |
| IgD, n (%) | 3 (3%) |
| Biclonal, n (%) | 2 (2%) |
| Light chain only, n (%) | 25 (25%) |
| Previous therapy | |
| ≤3 lines of therapy | 24 (24%) |
| >3 lines of therapy | 78 (76%) |
| Prior therapy to which disease was refractory*before start of daratumumab | |
| Lenalidomide refractory, n (%) | 86 (84%) |
| Bortezomib refractory, n (%) | 85 (83%) |
| Lenalidomide and bortezomib refractory, n (%) | 78 (76%) |
| Pomalidomide refractory, n (%) | 54 (53%) |
| Carfilzomib refractory, n (%) | 36 (35%) |
| Parameter . | MM patients (n = 102) . |
|---|---|
| Median age, years (range) | 64 (32-84) |
| Sex, male, n (%) | 57 (56%) |
| M-protein type | |
| IgG, n (%) | 51 (50%) |
| IgA, n (%) | 21 (21%) |
| IgM, n (%) | 0 (0%) |
| IgD, n (%) | 3 (3%) |
| Biclonal, n (%) | 2 (2%) |
| Light chain only, n (%) | 25 (25%) |
| Previous therapy | |
| ≤3 lines of therapy | 24 (24%) |
| >3 lines of therapy | 78 (76%) |
| Prior therapy to which disease was refractory*before start of daratumumab | |
| Lenalidomide refractory, n (%) | 86 (84%) |
| Bortezomib refractory, n (%) | 85 (83%) |
| Lenalidomide and bortezomib refractory, n (%) | 78 (76%) |
| Pomalidomide refractory, n (%) | 54 (53%) |
| Carfilzomib refractory, n (%) | 36 (35%) |
Refractory disease is defined as progressive disease during therapy, no response (less than PR), or progressive disease within 60 days of stopping treatment, according to the International Uniform Response Criteria for Multiple Myeloma.